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Background: In a phase II study, responses and toxicity to single-agent gemcitabine chemotherapy were evaluated
in patients with non-small-cell lung cancer (NSCLC) who had failed previous cisplatin-based chemotherapy.
Methods: Twenty patients were enrolled from December 2001 to December 2003: 17 of them had received first-
line cisplatin-based regimens and second-line docetaxel treatment; and 3 had previously received cisplatin plus
paclitaxel. Study treatment comprised an intravenous infusion of gemcitabine 1,200 mg/m2 on days 1, 8, and 15
of each 4-week cycle.
Results: Fifty-seven cycles of treatment were given (mean, 2.9 cycles per patient). All patients were evaluable for toxicity
profile, and 16 were evaluable for response rate. The principal toxicity was myelosuppression: grade 3 neutropenia
occurred in 2 patients (10%), thrombocytopenia in 3 (15%), and anemia in 1 (5%). Other toxicities were few and mild
in severity. After 2 cycles of treatment, 2 of 16 patients (12.5%) had a partial response. The median time to disease
progression was 2.1 months, and median survival time was 7.5 months. The 1-year survival rate was 36%.
Conclusion: Salvage, single-agent chemotherapy with gemcitabine has modest activity, is well tolerated, and yields
good survival in NSCLC patients who have failed previous chemotherapy. Such single-agent therapy may therefore be
suggested for use in patients with good performance status who ask for further chemotherapy, when disease progresses
after cisplatin-based therapy, but especially after second-line docetaxel therapy. [J Chin Med Assoc 2005;68(4):163–166]
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Introduction
Since first-line chemotherapy with new, platinum-based
agents for non-small-cell lung cancer (NSCLC) has
been documented as being superior to conventional
chemotherapy, the use of salvage therapy for cancer pa-
tients who fail primary chemotherapy is under active
investigation. Docetaxel, a novel anticancer agent, pro-
longed patient survival in phase III, randomized stud-
ies versus vinorelbine, ifosfamide, or best supportive
care, in NSCLC patients in whom previous chemother-
apy had failed,1,2 and has therefore been recommended
as a second-line treatment for NSCLC.3
Gemcitabine, a nucleoside analog with confirmed
activity against chemotherapy-naïve NSCLC,4 gen-
erally has few, and only mild, toxicities. Significant
adverse effects of gemcitabine that have an impact on
patient quality of life, or that require treatment with-
drawal, are reported to be less than with any other sin-
gle new agent or combination of agents.5 In addition,
gemcitabine is safe and easy to administer in an
outpatient setting.
Gemcitabine probably also has activity in the second-
line treatment of NSCLC, with a response rate to
single-agent therapy ranging from 6.0–20.6% in phase
II studies,6–10 and documented superior survival and
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response rates in phase III trials of gemcitabine plus
cisplatin versus cisplatin alone (or versus other cisplatin-
based conventional regimens).5 However, the poten-
tial roles of gemcitabine as second- and third-line
chemotherapy have not been well defined. Because of
the relatively favorable safety profile of gemcitabine,
and marked activity of the compound as first-line
chemotherapy for NSCLC, we conducted a phase II
study to determine the efficacy and toxicity profiles
of single-agent gemcitabine in NSCLC patients in
whom previous first-line, cisplatin-based, new-agent
chemotherapy had failed; several patients had also
received second-line docetaxel therapy.
Methods
Study population
Patients with NSCLC who had failed previous cisplatin-
based chemotherapy, and who were aged * 18 years,
were enrolled in the study after giving informed con-
sent. Eligibility criteria comprised the following: his-
tologic or cytologic diagnosis of stage IV NSCLC; per-
formance status of 0–2 on the Zubrod scale; clinically
measurable disease defined as bi-dimensionally mea-
surable lesions, with clearly defined margins on a
chest computed tomography (CT) scan; no previous
radiotherapy for measurable lesion(s); adequate
bone marrow reserve, with a white blood cell count
* 4,000/mm3, platelets * 100,000/mm3, and
hemoglobin * 10 g/dL; and no previous history of
gemcitabine treatment. Exclusion criteria comprised
the following: active infection; inadequate liver func-
tion (bilirubin > 1.5 times the normal range, alanine
aminotransferase and aspartate aminotransferase levels
> 3 times the upper limit of normal); and inadequate
renal function (serum creatinine > 2.0 mg/dL).
Study treatment
All patients received a 30-minute, intravenous infusion
of gemcitabine 1,200 mg/m2 on days 1, 8, and 15 of
each 4-week cycle. A complete blood cell count was
done in the 24 hours before chemotherapy. Serum
biochemistry studies were performed before every
course of chemotherapy, and during each course, if
clinically indicated. Drug-related adverse events and
toxicities were recorded, according to established
Eastern Cooperative Oncology Group (ECOG) cri-
teria.11
Within each cycle, the dose of gemcitabine was
reduced by 50% if absolute neutrophil count (ANC)
ranged from 1.0–1.5 = 109/L, and/or platelet count
ranged from 75–99 = 109/L, on the day of scheduled
chemotherapy; the dose was omitted if ANC was
< 1.0 = 109/L, or platelet count was < 75 = 109/L.
During each cycle, and in subsequent cycles, and for
toxicities other than nausea, vomiting and alopecia,
the dose of gemcitabine was reduced by 50% if grade
3, non-hematologic toxicities were noted; the dose
was omitted in case of grade 4 toxicities.
Study measurements
Baseline evaluations included documentation of
patient history, a physical examination, and an as-
sessment of performance score. A complete blood
cell count, urinalysis, serum biochemistry profile,
electrocardiogram, chest X-ray, whole-body bone
scan, brain CT scan, and chest (including liver and
adrenal glands) CT scan, were also performed.
Response was evaluated after the first 2 cycles of
chemotherapy, and after every 2 cycles thereafter. The
types of response were also assessed, according to
established ECOG criteria.11 Patients who responded,
and those with stable disease, continued treatment
until disease progression or the completion of 6 cy-
cles of treatment. Overall survival and time to disease
progression were analyzed using the Kaplan-Meier
estimation method. Survival was measured from the
time the first dose of gemcitabine was administered
until the time of death or last follow-up.
Results
Demographic data
Between December 2001 and December 2003, 20
patients (9 males; 11 females) were enrolled in the
study. Patient age ranged from 45–75 years (mean,
61.4 years), and performance status was 1 (n = 5) or
2 (n = 15). Regarding histologic sub-type, 7 patients
had adenocarcinoma, 5 had squamous cell carcinoma,
and 8 had other NSCLC. All patients had stage IV
disease, and all had undergone previous cisplatin-
based combination chemotherapy and taxane treatment
(paclitaxel as first-line, and/or docetaxel as second-
line treatment). Thus, gemcitabine was second-line
chemotherapy in 3 patients, and third-line therapy in
17 patients. All patients were evaluable for toxicity
profile, but 4 patients were unevaluable for response
(all were using gemcitabine as third-line therapy)
because they refused further treatment after the first
gemcitabine cycle.
Clinical findings
A total of 57 treatment cycles were administered (mean,
2.9 cycles per patient; median, 2 cycles per patient).
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After 2 cycles of treatment, 2 of 16 patients (12.5%;
95% confidence interval [CI], 0, 28.7) had a partial
response, stable disease was noted in 6 patients
(37.5%), and progressive disease was documented in
the remaining 8 (50%). The 2 patients with a partial
response had responded to third-line therapy. The
overall median time to disease progression was
2.1 months (95% CI, 1.4, 2.9), and overall median
survival was 7.5 months (95% CI, 1, 14) (Figure 1).
The 1-year survival rate was 36%. For the 17 patients
who received gemcitabine as third-line therapy, the
median survival time was 4.5 months.
Toxicity data
The principal toxicities were hematologic and were
mild in severity. There was no grade 4 hematologic
toxicity; however, grade 3 neutropenia occurred in
2 patients (10%), grade 3 thrombocytopenia occurred
in 3 (15%), and grade 3 anemia occurred in 1 (5%).
No febrile neutropenia occurred. Non-hematologic
toxicities were few and mild () grade 2).
Discussion
As the response rate to chemotherapy for patients in
whom previous chemotherapy has failed is usually low
() 25%),12 the options available to patients with
advanced NSCLC resistant or refractory to first-line
chemotherapy are very limited. However, as new
anticancer drugs and their combinations with cisplatin
have recently shown better response rates and survival
than conventional regimens, increased survival has
become the main motivation when considering second-
line chemotherapy for NSCLC. Since 2003, after
several clinical trials of new anticancer agents as sal-
vage chemotherapy, docetaxel has been suggested as
standard, second-line chemotherapy, whereas gefitinib
has been suggested for patients in whom both platinum-
based and docetaxel chemotherapies have failed.3
When considering salvage chemotherapy with
second-line or subsequent regimens, symptomatic relief
and low rates of treatment-related toxicity are relatively
more important than the pursuit of high response rates.
In phase II trials, the response rate to single-agent
gemcitabine as second-line therapy for NSCLC has
ranged from 6.0–20.6%; median survival has ranged
from 4–7.9 months.6–10 The present study revealed a
response rate of 12.5% and a median survival of 7.5
months; these values are within the aforementioned
ranges. The toxicity of single-agent gemcitabine therapy
has been minimal and mild in severity, both in the
present and previous studies.6–10 The present trial also
identified a median survival time of 4.5 months, together
with very mild toxicity, in the 17 patients receiving
gemcitabine as third-line therapy. This finding warrants
further clinical study, even though median survival was
shorter than that reported for daily, oral gefitinib therapy
in the Iressa® Dose Evaluation in Advanced Lung
Cancer (IDEAL)-2 study, in which previous platinum-
based combination chemotherapy and docetaxel regi-
mens had also failed.13
Other commonly used and investigated, non-
platinum-based, salvage chemotherapies are gemcitabine
plus taxanes or vinorelbine.14–18 These regimens have
been evaluated in phase II studies, but patient survival
was not significantly better than that in previous studies
of single-agent docetaxel therapy,1,2 even though
response rates may be greater with the combination
schedules. Importantly, gemcitabine (plus taxanes or
vinorelbine) is well tolerated and relatively safe, and is
an active salvage regimen in patients with NSCLC
in whom previous platinum-based chemotherapy has
failed. From the results of our study, gemcitabine
alone is also a well-tolerated agent with modest activ-
ity, even in patients who have undergone previous
first-line, platinum-based, combination chemotherapy
and second-line docetaxel therapy.
In summary, gemcitabine is an effective salvage
regimen for NSCLC patients in whom previous che-
motherapy has failed. This agent may be suggested
for patients who ask for further chemotherapy, when
they experience disease progression after cisplatin-
based chemotherapy, but especially after second-line
docetaxel therapy. Further studies of single-agent
gemcitabine therapy, such as a comparison with
gefitinib, now warrant consideration, particularly in
patients for whom both cisplatin-based chemotherapy
and second-line docetaxel therapy have failed.
Figure 1. Kaplan-Meier survival curve for 20 patients with non-
small-cell lung cancer treated with gemcitabine. The overall
median survival was 7.5 months and the 1-year survival rate
was 36%.
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